Cardiogenic shock is the most feared complication of acute myocardial infarction and the leading cause of in-hospital death from MI. The heart loses its ability to maintain adequate cardiac output, and the result is a cascade of circulatory failure, organ hypoperfusion, and — without rapid, coordinated intervention — death. Mortality rates remain 30–50% in contemporary practice despite advances in revascularization, mechanical circulatory support, and critical care. Nurses are at the center of the response: monitoring hemodynamics, titrating vasoactive infusions, managing invasive devices, and identifying early deterioration before it becomes irreversible. This guide covers the full scope of cardiogenic shock nursing — from hemodynamic definition through vasopressors, mechanical support, revascularization urgency, and multi-organ failure prevention — with NCLEX high-yield tips throughout.
Quick reference: cardiogenic shock at a glance
| Parameter | Diagnostic threshold | Clinical significance |
|---|---|---|
| Systolic blood pressure | <90 mmHg for ≥30 min despite adequate volume, or requiring vasopressors to maintain ≥90 | Persistent hypotension signals pump failure |
| Mean arterial pressure (MAP) | <65 mmHg despite vasopressors; target ≥65 mmHg during treatment | MAP drives perfusion to kidneys, brain, gut |
| Cardiac index (CI) | <2.2 L/min/m² (severe: <1.8 L/min/m²) | Quantifies degree of pump failure |
| Pulmonary capillary wedge pressure (PCWP) | >15 mmHg | Reflects elevated LV filling pressure and pulmonary congestion |
| Urine output | <0.5 mL/kg/hr | Early marker of renal hypoperfusion |
| Serum lactate | Elevated (>2 mmol/L); trend matters as much as absolute value | Reflects anaerobic metabolism from tissue ischemia |
| ScvO₂ / SvO₂ | <65% indicates high oxygen extraction (tissues starved) | Goal >65%; rising trend signals improving CI |
| Key nursing interventions | Arterial line, central line, Foley, continuous hemodynamic monitoring, vasopressors/inotropes, MCS device management, early revascularization coordination | |
Definition and hemodynamic criteria
Cardiogenic shock is defined as sustained end-organ hypoperfusion caused by primary cardiac dysfunction — the pump fails, cardiac output drops, and tissues cannot receive adequate oxygen delivery. It is a hemodynamic diagnosis, not merely a blood pressure reading.
The classic diagnostic criteria, used in landmark clinical trials and AHA guidelines, require all of the following:
- Systolic BP <90 mmHg for 30 minutes or longer despite adequate volume resuscitation, or requiring vasopressor/inotropic support to maintain SBP ≥90 mmHg
- Cardiac index <2.2 L/min/m² (some criteria for severe CS use <1.8 L/min/m²)
- PCWP >15 mmHg — elevated filling pressures distinguish cardiogenic from hypovolemic shock
- Evidence of end-organ hypoperfusion — at least one of: oliguria (<0.5 mL/kg/hr), altered mental status, cool and clammy extremities, elevated lactate (>2 mmol/L)
The PCWP criterion is critical. Unlike distributive shock (sepsis, anaphylaxis), cardiogenic shock patients are not volume-depleted — their filling pressures are elevated because the failing ventricle cannot eject effectively. Large fluid boluses worsen pulmonary edema without improving output. This distinction drives management.
Clinical signs at the bedside
Before invasive hemodynamics are established, nurses rely on clinical signs:
- Skin: cool, clammy, mottled — peripheral vasoconstriction as the body redirects flow to vital organs
- Extremities: diminished pulses, prolonged capillary refill (>2 seconds)
- Mentation: restlessness, confusion, agitation — the brain is hypoperfused
- Urine output: falling below 0.5 mL/kg/hr is an early warning; anuria signals severe organ compromise
- Respiratory: tachypnea, hypoxia, crackles — pulmonary edema from backward failure
- Heart sounds: S3 or S4 gallop; new murmur may indicate acute valvular emergency
Pathophysiology: the cardiogenic shock spiral
Understanding the pathophysiology helps nurses anticipate deterioration and understand why treatments are chosen.
The initial injury
In the most common scenario — STEMI with large anterior infarct — the left ventricle loses 40% or more of its contractile mass. Systolic dysfunction reduces stroke volume. The left ventricle cannot empty effectively, so end-diastolic volume and pressure rise. This backward pressure transmits to the pulmonary vasculature: PCWP rises, fluid weeps into the alveoli, and oxygenation falls.
The compensatory response that worsens the problem
The body detects falling cardiac output via baroreceptors and activates the sympathetic nervous system. Heart rate rises (compensatory tachycardia) and systemic vascular resistance increases (vasoconstriction). Both responses are initially protective but become self-defeating in cardiogenic shock:
- Tachycardia shortens diastolic filling time, reducing stroke volume further. It also increases myocardial oxygen demand in a heart that is already ischemic.
- Vasoconstriction raises afterload — the resistance the left ventricle must overcome to eject. A failing ventricle pumps even less effectively against a higher resistance. Cardiac output falls further.
The result is a vicious cycle: reduced CO → compensatory vasoconstriction → increased afterload → worse CO → more vasoconstriction. Without interruption — via vasodilators, inotropes, mechanical unloading, or revascularization — the spiral accelerates.
Prolonged shock: the inflammatory cascade
In shock lasting more than a few hours, myocardial ischemia triggers an inflammatory cascade: cytokine release, reactive oxygen species, and nitric oxide production. This causes vasodilation (a paradoxical vasoplegic component) and mitochondrial dysfunction, further impairing both cardiac and peripheral tissue metabolism. Elevated lactate reflects the shift to anaerobic metabolism. Multi-organ failure begins as the gut, kidneys, and liver sustain ischemic injury.
Causes and Killip classification
Etiology of cardiogenic shock
ST-elevation MI (STEMI) is the most common cause, accounting for approximately 80% of cardiogenic shock cases. Large anterior wall infarctions involving the left anterior descending artery carry the highest risk. Right ventricular infarction (from proximal right coronary artery occlusion) causes a distinct presentation with elevated JVP, clear lung fields, hypotension — and responds to cautious volume rather than diuresis.
Other causes include:
- NSTEMI / unstable angina with large territory involvement
- Acute decompensated heart failure — end-stage cardiomyopathy (ischemic or non-ischemic)
- Myocarditis — viral, autoimmune, or giant cell; can be fulminant with sudden hemodynamic collapse
- Severe valvular disease — acute mitral regurgitation from papillary muscle rupture post-MI; acute aortic stenosis decompensation; aortic regurgitation from dissection
- Takotsubo (stress) cardiomyopathy — transient apical ballooning, typically in post-menopausal women after acute emotional or physiologic stress; usually reversible
- Massive pulmonary embolism — technically obstructive shock but managed with similar urgency; RV afterload crisis
- LVAD malfunction — pump thrombosis or driveline failure causing loss of mechanical circulatory support in a patient dependent on it (see LVAD nursing guide)
Killip classification
The Killip-Kimball classification, developed in 1967, stratifies patients with acute MI by clinical evidence of heart failure. It remains one of the most powerful prognostic tools in acute cardiac care.
| Class | Clinical criteria | Hemodynamic features | Estimated in-hospital mortality |
|---|---|---|---|
| Class I | No signs of heart failure. No S3. No rales. | Normal cardiac output, normal filling pressures | ~6% |
| Class II | Mild to moderate heart failure. Bibasilar rales (less than half lung fields), S3 gallop, elevated JVP | Mildly reduced CI; elevated PCWP | ~17% |
| Class III | Severe heart failure. Frank pulmonary edema — rales throughout both lung fields | Significantly reduced CI; markedly elevated PCWP | ~38% |
| Class IV | Cardiogenic shock: hypotension (SBP <90), cool clammy skin, oliguria, altered mentation | CI <2.2 L/min/m², PCWP >15 mmHg, MAP <65 | ~40–80% (contemporary estimates 40–50%; original 1967 data reported 81%) |
Note: Killip Class IV mortality has decreased substantially from the 1967 era as revascularization and mechanical circulatory support became available, but it remains the highest-risk category by far.
Initial stabilization
Speed matters. The priority in the first minutes is establishing monitoring, securing access, and beginning hemodynamic support while simultaneously arranging definitive treatment (revascularization).
ABCs and positioning
- Airway: Assess immediately. Many cardiogenic shock patients require intubation — either for respiratory failure from pulmonary edema or for airway protection with altered mentation. Anticipate intubation; have equipment at bedside.
- Breathing: Apply supplemental oxygen to target SpO₂ ≥94%. Non-invasive ventilation (CPAP, BiPAP) may temporize pulmonary edema and reduce intubation urgency in stable patients. Lung-protective ventilation settings once intubated.
- Circulation: Begin hemodynamic monitoring immediately.
- Positioning: Head of bed at 30 degrees to reduce aspiration risk and ease respiratory work. Avoid Trendelenburg — it increases venous return and worsens pulmonary congestion in a patient who is already volume-overloaded.
Vascular access
- Two large-bore peripheral IVs — minimum 18-gauge, 16-gauge preferred for rapid drug/blood administration
- Central venous access — internal jugular or subclavian preferred; needed for vasopressors, CVP monitoring, and ScvO₂ sampling. For central line insertion and care, see the central line nursing guide.
- Arterial line — essential for continuous beat-to-beat blood pressure monitoring and frequent arterial blood gas sampling. Radial artery is standard first choice. See the arterial line nursing guide for insertion and troubleshooting.
- Foley catheter — urine output is a critical perfusion marker; accurate hourly measurement is non-negotiable
The fluid trap: do not bolus freely
The instinct in a hypotensive patient is to give fluid. In cardiogenic shock, this instinct must be resisted. These patients have:
- Elevated PCWP (often 20–30 mmHg) — filling pressures are already high
- A failing ventricle that cannot accommodate increased preload
- Risk of flash pulmonary edema with even modest fluid administration
Small, cautious fluid challenges (250 mL) may be considered if there is genuine concern about concurrent hypovolemia (e.g., right heart failure without pulmonary edema, or mixed shock). Otherwise, fluid management focuses on diuresis to reduce congestion — not resuscitation.
This is the key distinction from septic shock. In sepsis nursing, early goal-directed fluid resuscitation (30 mL/kg) is standard. In cardiogenic shock, the same approach can be lethal.
Invasive hemodynamic monitoring
Once the patient is stabilized and central access is in place:
- Arterial line for continuous MAP and waveform trending
- Pulmonary artery catheter (PAC) — indicated in complex or refractory shock to measure CO/CI, PCWP, SVR, and mixed venous oxygen saturation. The PAC guides vasopressor and inotrope titration with precision unavailable from clinical assessment alone. For full detail on PAC placement and interpretation, see the pulmonary artery catheter nursing guide.
Vasopressor and inotrope selection
Pharmacologic support is the bridge to definitive therapy. The goal is to maintain MAP ≥65 mmHg and improve cardiac output while minimizing myocardial oxygen demand. The choice of agent depends on the hemodynamic profile.
Understanding the hemodynamic profile first
Before choosing a drug, identify the dominant problem:
- Low MAP with preserved CI → vasopressor (raise SVR/MAP)
- Low CI with adequate MAP → inotrope (improve contractility)
- Low MAP and low CI → vasopressor + inotrope combination
For a comprehensive review of vasoactive agents, mechanisms, and dosing, see the vasopressors and inotropes nursing guide.
Vasopressor selection: norepinephrine first
The SOAP-II trial (De Backer et al., NEJM 2010) was a landmark randomized controlled trial comparing dopamine to norepinephrine as first-line vasopressor for all shock states, including a cardiogenic shock subgroup (n=280).
Key findings:
- Overall 28-day mortality was not significantly different (52.5% dopamine vs 48.5% norepinephrine; p=0.10)
- In the cardiogenic shock subgroup, dopamine was associated with significantly higher 28-day mortality (p=0.03)
- Arrhythmic events were nearly double with dopamine: 24.1% vs 12.4% (p<0.001)
- Severe arrhythmia requiring drug discontinuation: 6.1% (dopamine) vs 1.6% (norepinephrine)
Clinical implication: Norepinephrine is the preferred first-line vasopressor for cardiogenic shock. Dopamine’s higher arrhythmia burden and worse outcomes in the shock subgroup make it a poor choice in a population already prone to ventricular arrhythmias.
Inotropes: when the pump needs a push
When CI remains low despite adequate MAP (or when the patient cannot tolerate vasopressor-driven increases in afterload), inotropic support is added:
Dobutamine — the first-line inotrope for cardiogenic shock
- Mechanism: primarily beta-1 agonist; increases contractility and heart rate; modest vasodilatory effect via beta-2 stimulation
- Dose range: 2–20 mcg/kg/min, titrated to CI/SvO₂ improvement
- Side effects: tachycardia, hypotension (vasodilation at higher doses), arrhythmias, tolerance with prolonged use
- Clinical role: improves CI when SBP/MAP are maintained; often used in combination with norepinephrine
Milrinone — second-line inotrope; phosphodiesterase-3 inhibitor
- Mechanism: prevents cAMP breakdown → increased contractility and vasodilation (inodilatation)
- Advantage over dobutamine: does not require beta-receptor stimulation (useful in patients on chronic beta-blockers)
- Disadvantage: renal clearance — use caution in AKI; longer half-life makes titration less flexible
- May cause significant hypotension; requires adequate MAP before initiation
Vasopressin — adjunct for refractory hypotension
- Mechanism: V1 receptor-mediated vasoconstriction; does not increase heart rate or myocardial oxygen demand
- Typical dose: 0.03–0.04 units/min fixed infusion as add-on to norepinephrine
- Role: allows norepinephrine dose reduction (reduces adrenergic burden) in vasoplegic or refractory shock
| Drug | Mechanism | Typical dose range | When to use | Key side effects / nursing considerations |
|---|---|---|---|---|
| Norepinephrine | Alpha-1 > beta-1; vasoconstriction + mild inotropy | 0.01–3 mcg/kg/min | First-line vasopressor for cardiogenic shock; MAP <65 despite volume | Peripheral ischemia at high doses; requires central line; monitor lactate, urine output |
| Dopamine | Dose-dependent: DA1 (renal) → beta-1 → alpha-1 | 5–20 mcg/kg/min | Second-line (avoid in cardiogenic shock if possible); bradycardic hypotension | High arrhythmia incidence (SOAP-II); worse outcomes in CS subgroup; tachycardia |
| Dobutamine | Beta-1 > beta-2; positive inotropy, mild vasodilation | 2–20 mcg/kg/min | Low CI despite adequate MAP; add to norepinephrine when pump failure dominates | Tachycardia, arrhythmias, hypotension at high doses; tolerance over days |
| Milrinone | PDE-3 inhibitor; inodilatation (↑ CO, ↓ SVR) | 0.125–0.75 mcg/kg/min (no loading dose in CS) | Low CI in patients on chronic beta-blockers; second-line if dobutamine not tolerated | Hypotension; renal clearance (dose-reduce in AKI); long half-life; avoid if MAP borderline |
| Vasopressin | V1 receptor; vasconstriction without beta-stimulation | 0.01–0.04 units/min (fixed infusion) | Adjunct to norepinephrine in refractory vasoplegic shock; reduces adrenergic load | Coronary vasoconstriction at high doses; hyponatremia; mesenteric ischemia |
| Epinephrine | Alpha and beta agonism; powerful vasoconstrictor + inotrope | 0.01–1 mcg/kg/min | Refractory shock when NE + dobutamine insufficient; cardiac arrest | Marked tachycardia, arrhythmias, extreme metabolic acidosis; lactic acidosis (non-hypoperfusion) |
Vasopressor weaning
Once the underlying cause is treated (revascularization, MCS), begin weaning vasoactive support based on hemodynamic stability:
- Target MAP ≥65 mmHg on declining doses
- Wean inotropes before vasopressors (once CI improves)
- Lactate trending to normal (<2 mmol/L) and urine output ≥0.5 mL/kg/hr are reliable weaning guides
- Abrupt discontinuation risks hemodynamic collapse; titrate down in 10–20% increments
Mechanical circulatory support
When pharmacologic therapy cannot maintain adequate perfusion, mechanical circulatory support (MCS) devices provide hemodynamic augmentation while the underlying cause is treated. Each device has a distinct mechanism, invasiveness level, and nursing management profile.
Intra-aortic balloon pump (IABP)
The IABP — a balloon positioned in the descending thoracic aorta — inflates during diastole to augment coronary perfusion and deflates before systole to reduce afterload. For complete IABP nursing management, see the IABP nursing guide.
The IABP-SHOCK II trial context: In 2012, the IABP-SHOCK II trial (Thiele et al., NEJM) randomized 600 patients with MI-related cardiogenic shock to IABP vs. control. The primary finding was no reduction in 30-day mortality, 12-month mortality, or 6-year mortality. Adverse event rates were similar between groups.
Clinical implication: IABP does not improve survival in MI-complicated cardiogenic shock but is associated with an acceptable safety profile. It remains widely used — particularly at smaller centers without Impella access — for afterload reduction and hemodynamic stabilization, despite the neutral trial evidence.
Impella (axial flow pump)
The Impella family are catheter-mounted micro-axial flow pumps that draw blood from the left ventricle and expel it into the ascending aorta, directly unloading the LV and increasing forward flow. They represent a higher tier of MCS than IABP.
Device models and flow capacity:
- Impella CP — inserted via femoral artery; provides up to ~3.5–4.0 L/min flow support; most commonly used in cardiogenic shock
- Impella 5.5 — inserted via axillary artery (surgical cutdown); provides up to 5.5 L/min; suitable for prolonged support (up to 14 days) and bridging to recovery or transplant
- Impella ECP (expandable catheter pump) — newer platform with enhanced flow characteristics via expandable impeller; emerging use in high-risk PCI and refractory CS
Key nursing points for Impella:
- Confirm positioning with waveform display on console — the inflow area must remain in the LV, not the ascending aorta
- Monitor for hemolysis — free hemoglobin, hematuria, LDH elevation; report to provider
- Anticoagulation is mandatory — typically heparin infusion with aPTT target per institutional protocol; monitor closely
- Assess limb perfusion hourly — femoral site (CP) is at risk for limb ischemia; check pulses, temperature, sensation
- Monitor purge solution system — prevents blood backflow into the catheter; alarm management is device-specific
Veno-arterial extracorporeal membrane oxygenation (VA-ECMO)
VA-ECMO provides simultaneous oxygenation and circulatory support, making it the most powerful MCS option for refractory cardiogenic shock. Blood is drained from the venous system (typically femoral vein), oxygenated and CO₂-removed by the membrane oxygenator, then returned via the arterial system (femoral artery), bypassing the native cardiopulmonary system.
When VA-ECMO is used:
- Cardiogenic shock refractory to maximal pharmacologic and IABP/Impella support
- Bridge to decision: recovery, durable LVAD, or cardiac transplant
- Cardiac arrest with suspected recoverable cause (ECPR — extracorporeal CPR)
- Fulminant myocarditis, massive PE
Nursing considerations specific to VA-ECMO:
- Monitor “north-south syndrome” (Harlequin syndrome) — differential hypoxia where upper body (supplied by native heart) may be hypoxic while lower body (supplied by ECMO return) is well-oxygenated; requires pulse oximetry on right hand and continuous review
- Limb ischemia risk is higher than with IABP — large cannula size requires distal perfusion catheter in the femoral vessel; assess limb hourly
- LV distension can occur — ECMO increases afterload; monitor for worsening pulmonary edema, loss of aortic valve pulsatility; IABP or Impella may be added for LV venting
- Anticoagulation is continuous — heparin or bivalirudin; ACT or aPTT per protocol
- Circuit monitoring: flow rates, sweep gas (oxygenation/CO₂ removal), membrane oxygenator condition, pump RPM, and oxygenator appearance (darkening suggests clot)
| Feature | IABP | Impella CP | Impella 5.5 | VA-ECMO |
|---|---|---|---|---|
| Flow support | ~0.5–1.0 L/min augmentation (indirect) | ~3.5–4.0 L/min | Up to 5.5 L/min | 3–7 L/min (full cardiac output) |
| Oxygenation support | No | No | No | Yes — full gas exchange |
| Invasiveness | Percutaneous femoral; 7–8 Fr sheath | Percutaneous femoral; 14 Fr | Surgical axillary cutdown; 21 Fr | Percutaneous or surgical; large bore cannulae |
| LV unloading | Indirect (afterload reduction) | Direct | Direct (most complete) | Increases afterload; may need LV vent |
| Key nursing monitoring | Waveform timing, limb pulses, balloon position, no kinking | Console positioning alarms, hemolysis labs, limb perfusion, anticoagulation | Axillary site care, hemolysis, anticoagulation, positioning | Circuit integrity, sweep gas, north-south syndrome, LV distension, cannula sites |
| Trial evidence | IABP-SHOCK II: no mortality benefit | DanGer Shock (2024): first RCT showing MCS mortality benefit | Observational; bridging to transplant/LVAD | No large RCT; used as bridge/rescue |
| Duration | Days to weeks | Up to 4 days (FDA approved) | Up to 14 days | Days to weeks depending on indication |
Revascularization urgency
In STEMI-complicated cardiogenic shock, restoring blood flow to the occluded artery is the definitive treatment — no amount of vasoactive support reverses ischemic pump failure if the infarct is still evolving. Speed to revascularization is directly linked to survival.
Primary PCI: the standard of care
Emergency percutaneous coronary intervention (PCI) is the revascularization strategy of choice for STEMI with cardiogenic shock. The cath lab must be activated immediately — do not delay PCI for hemodynamic stabilization beyond what is essential (arterial line, vasopressors running, airway secured).
Call cardiology and the catheterization laboratory the moment cardiogenic shock is suspected. Do not wait for complete workup.
The CULPRIT-SHOCK trial: culprit-only vs. multivessel PCI
Many STEMI patients with cardiogenic shock have multivessel coronary artery disease. An important clinical question is whether to treat only the culprit artery causing the infarct, or to revascularize all significant stenoses during the same procedure.
The CULPRIT-SHOCK trial (Thiele et al., NEJM 2017 and 2018) directly addressed this. Key findings:
- Primary endpoint (30-day death or severe renal failure requiring RRT): 45.9% culprit-only vs. 55.4% multivessel PCI (RR 0.83; p=0.01)
- 30-day mortality: 43.3% culprit-only vs. 51.5% multivessel PCI (RR 0.84; p=0.03)
- At 1-year follow-up, the mortality benefit of culprit-only PCI persisted (no catch-up effect in the multivessel group)
Clinical implication: In cardiogenic shock complicating STEMI with multivessel disease, treat the culprit lesion only at the initial procedure. Staged revascularization of non-culprit lesions can be performed after the patient stabilizes. Immediate multivessel PCI causes more harm than benefit — likely because contrast load, procedure duration, and reperfusion injury from multiple vessels worsens already-compromised physiology.
CABG and thrombolytics
- CABG is indicated for patients with left main or multivessel anatomy not amenable to PCI, or mechanical complications of MI (acute VSD, papillary muscle rupture) requiring surgical repair. Operative mortality is high in active shock but surgery may be life-saving.
- Thrombolytics are reserved for settings where primary PCI is unavailable within 120 minutes of first medical contact. The risk of bleeding is significant, and reperfusion is less complete than PCI.
Nursing monitoring in cardiogenic shock
Cardiogenic shock patients are some of the highest-acuity patients in any ICU. Monitoring must be continuous, systematic, and interpreted in trend — no single data point is decisive.
Hemodynamic targets and monitoring frequency
| Parameter | Target | Monitoring frequency |
|---|---|---|
| MAP | ≥65 mmHg | Continuous (arterial line) |
| Urine output | ≥0.5 mL/kg/hr | Hourly |
| Serum lactate | <2 mmol/L; trending down | q2–4h initially; q6h once trending |
| ScvO₂ (central venous) | ≥65% | Per PAC or q4–8h sampling |
| SvO₂ (mixed venous via PAC) | ≥65% | Continuous if PAC oximetry capable |
| Cardiac index (if PAC in situ) | ≥2.2 L/min/m² | q1–4h per protocol |
| PCWP | 15–20 mmHg during treatment | q4–8h via PAC |
| Heart rate | 60–100 bpm; minimize tachycardia | Continuous ECG monitoring |
Skin and perfusion assessment
Repeat perfusion assessment every 1–2 hours:
- Capillary refill time — goal <2 seconds; prolonged suggests persistent peripheral vasoconstriction
- Skin temperature and color — mottling is a sign of severe hypoperfusion; distribution and extent matter (isolated limb vs. trunk)
- Peripheral pulses — assess bilateral radial, dorsalis pedis, posterior tibial; compare to baseline
Neurological status
Monitor orientation, Glasgow Coma Scale, and behavior every hour. Acute agitation or new confusion in a previously oriented patient may signal worsening cerebral perfusion before the blood pressure numbers change. Sedation decisions in intubated patients must account for the hemodynamic effects of sedative agents (propofol and benzodiazepines can drop MAP substantially).
Ventilator management (if intubated)
Most patients in florid cardiogenic shock require intubation. Lung-protective ventilation reduces additional injury:
- Tidal volume: 6–8 mL/kg ideal body weight
- PEEP: titrate to oxygenation; high PEEP reduces venous return and may worsen RV function
- Plateau pressure <30 cmH₂O
- SpO₂ target 94–98%; PaO₂ 60–80 mmHg to avoid oxygen toxicity
- Note: intubation itself is a hemodynamic event — loss of sympathetic tone with induction agents can cause precipitous BP drop; have vasopressors ready to bolus
Lines and device care
- Arterial line: Level transducer at phlebostatic axis (4th ICS, midaxillary line); zero q8h or after position change; assess insertion site for hematoma or infection; document waveform quality
- Central line: Daily dressing assessment; CLABSI bundle compliance (maximal sterile barrier, chlorhexidine site care, daily necessity assessment); central line nursing guide
- MCS devices: Per device-specific protocols; no bending or kinking; positioning restrictions per device (IABP — patient must not flex hip beyond 30°; Impella CP — similar femoral access restriction)
Multi-organ failure: recognition and prevention
Cardiogenic shock is systemic. The failing heart hypoperfuses every organ simultaneously, and multi-organ failure (MOF) is both a consequence of shock and a driver of further deterioration.
Acute kidney injury (AKI)
AKI is the most common organ complication in cardiogenic shock, occurring in 50–70% of patients. Cardiorenal syndrome develops as reduced renal perfusion (low CO) combines with venous congestion (elevated CVP transmitted to renal veins), impairing both afferent and efferent renal blood flow.
Monitor:
- Hourly urine output — a sustained fall below 0.5 mL/kg/hr triggers escalation
- Daily serum creatinine and BUN — a rise of ≥0.3 mg/dL within 48 hours meets AKI criteria
- Avoid nephrotoxins: NSAIDs, contrast (minimize during PCI if possible), aminoglycosides
- Renal replacement therapy (CRRT preferred for hemodynamically unstable patients) may be required
Hepatic injury (cardiogenic hepatopathy)
The liver is exquisitely sensitive to both low-output ischemia (centrilobular necrosis — “shock liver”) and elevated CVP from right heart failure (passive hepatic congestion).
Monitor:
- AST, ALT, bilirubin — transaminases can peak at 500–5,000 U/L in acute ischemic hepatitis
- PT/INR — hepatic synthetic function; rising INR signals significant hepatocyte loss
- Right upper quadrant tenderness on exam
Coagulopathy and DIC
Prolonged circulatory shock activates coagulation pathways. Disseminated intravascular coagulation (DIC) can develop with simultaneous microvascular thrombosis and consumption of clotting factors.
Monitor: fibrinogen (falling), D-dimer (rising), PT, aPTT, platelet count. DIC screen should be drawn on admission and daily in unstable patients.
Gastrointestinal ischemia
The splanchnic circulation is among the first to vasoconstrict in low-output states. Gut ischemia causes:
- Ileus — absent bowel sounds, abdominal distension, intolerance of enteral nutrition
- Translocation of gut bacteria — drives systemic infection and SIRS
- Stress ulceration — gastric mucosal ischemia; stress ulcer prophylaxis (PPI or H₂ blocker) is standard
Infection prevention
Patients with cardiogenic shock have multiple infection vectors: central venous catheters, arterial lines, urinary catheters, mechanical ventilation, and MCS device cannula sites.
Prevention bundles:
- CLABSI: maximal sterile barrier at insertion, daily necessity assessment, chlorhexidine dressings, hub disinfection protocol
- CAUTI: smallest Foley lumen sufficient; remove when no longer needed for hourly monitoring
- VAP: head of bed 30–45°, oral decontamination every 4–6 hours, daily sedation vacation and spontaneous breathing trial assessment, subglottic secretion drainage
- MCS site care: sterile dressings per manufacturer protocol; daily site assessment for erythema, exudate, or signs of local infection
Nursing diagnoses and care plan
Decreased cardiac output
Related to: myocardial damage (infarction, ischemia, cardiomyopathy), valvular dysfunction, dysrhythmias
Evidence: hypotension, tachycardia, reduced cardiac index, poor peripheral perfusion, declining urine output
Nursing interventions:
- Continuous hemodynamic monitoring; MAP target ≥65 mmHg
- Administer vasoactive medications as prescribed; titrate per MAP and CI parameters
- Minimize increases in myocardial oxygen demand (pain management, fever control, sedation for intubated patients)
- Prepare for and assist with MCS device insertion if escalation ordered
- Document response to interventions at least hourly
Impaired tissue perfusion (peripheral and renal)
Related to: reduced cardiac output, compensatory vasoconstriction, hypotension
Evidence: cool/mottled extremities, capillary refill >2 seconds, oliguria, rising creatinine, altered mentation
Nursing interventions:
- Hourly urine output measurement; escalate if <0.5 mL/kg/hr for 2 consecutive hours
- Lactate and ScvO₂ trending; communicate worsening values to provider immediately
- Skin and limb assessment every 1–2 hours; document mottling extent and distribution
- Careful positioning to protect heels and bony prominences
Risk for fluid volume imbalance
Related to: impaired ventricular filling/emptying, pharmacologic diuresis, contrast load from PCI
Evidence/risk factors: elevated PCWP, pulmonary edema, diuretic therapy, contrast nephropathy risk
Nursing interventions:
- Strict intake and output; fluid balance calculated every 8 hours
- Daily weights when patient is stable enough
- Monitor for signs of fluid overload (rising PCWP, worsening SpO₂, increasing respiratory rate)
- Administer diuretics as ordered; monitor electrolytes — aggressive diuresis depletes potassium and magnesium, increasing arrhythmia risk
Anxiety and ineffective coping
Related to: life-threatening diagnosis, invasive procedures, ICU environment, uncertainty
Evidence: verbalized fear, inability to concentrate, agitation, requests for reassurance
Nursing interventions:
- Provide clear, calm, honest explanations before each procedure
- Allow family presence at bedside whenever hemodynamically feasible
- Minimize unnecessary alarms and noise
- Coordinate with social work and chaplaincy for family support
- Assess for delirium (CAM-ICU) — ICU delirium is common in cardiogenic shock and worsens outcomes
Cardiac arrhythmias in cardiogenic shock
Arrhythmias both cause and complicate cardiogenic shock. For detailed arrhythmia recognition and management, see the cardiac arrhythmias nursing guide.
In cardiogenic shock specifically:
- Ventricular fibrillation and pulseless VT require immediate defibrillation; keep defibrillator charged and accessible at all times
- Ventricular tachycardia (with pulse) — may be tolerated briefly but causes hemodynamic deterioration; requires cardioversion or antiarrhythmic therapy (amiodarone is preferred)
- Atrial fibrillation — a common complication; ventricular rate control is priority; beta-blockers are usually contraindicated in acute CS; amiodarone or digoxin may be used
- Bradycardia — particularly in right coronary artery occlusion with inferior MI; may require transcutaneous or transvenous pacing; atropine has limited efficacy in junctional rhythms
- Electrolyte derangements (hypokalemia, hypomagnesemia from diuresis or poor intake) lower the arrhythmia threshold — replace potassium to target 4.0–4.5 mEq/L and magnesium to 2.0 mEq/L
NCLEX high-yield tips
| # | High-yield tip |
|---|---|
| 1 | Cardiogenic shock is defined by low CO + high filling pressure (PCWP >15 mmHg). This distinguishes it from hypovolemic shock (low CO + low filling pressure). |
| 2 | Do NOT give large fluid boluses in cardiogenic shock — patients are fluid-overloaded, and boluses worsen pulmonary edema. This is the opposite of septic shock management. |
| 3 | Norepinephrine is the first-line vasopressor for cardiogenic shock, per SOAP-II trial evidence. Dopamine has a higher arrhythmia incidence and worse outcomes in the CS subgroup. |
| 4 | Killip Class IV (cardiogenic shock) carries the highest mortality of any Killip class — in-hospital mortality 40–80% depending on era and treatment setting. |
| 5 | CULPRIT-SHOCK trial: in STEMI with cardiogenic shock and multivessel disease, culprit-only PCI is superior to immediate multivessel PCI for 30-day mortality. |
| 6 | IABP-SHOCK II trial: IABP did not reduce mortality in MI-complicated cardiogenic shock. It remains in use but is no longer a Class I indication. |
| 7 | The classic triad of cardiogenic shock on exam: cool/clammy skin + hypotension + altered mentation + oliguria. |
| 8 | Urine output goal in cardiogenic shock is ≥0.5 mL/kg/hr. Below this, the kidney is not being adequately perfused — escalate. |
| 9 | Dobutamine increases contractility (inotrope); norepinephrine increases vascular resistance (vasopressor). They address different components of cardiac output. |
| 10 | Milrinone works via PDE-3 inhibition (does not need beta receptors). Choose milrinone over dobutamine in patients on chronic beta-blockers. |
| 11 | Serum lactate >2 mmol/L is a marker of anaerobic metabolism. A rising lactate despite vasopressors signals worsening shock, not improvement. |
| 12 | ScvO₂ <65% means tissues are extracting more oxygen than normal — cardiac output is inadequate. ScvO₂ goal is ≥65%. |
| 13 | Right ventricular infarction presents with elevated JVP, hypotension, and clear lung fields — treat with cautious fluid (different from LV failure). |
| 14 | Impella CP provides direct LV unloading and forward flow up to ~4 L/min. IABP provides indirect support (~0.5–1 L/min augmentation) — they are not equivalent. |
| 15 | VA-ECMO provides both circulatory support and oxygenation — it can support full cardiac output. It is the most powerful MCS but also the most invasive. |
| 16 | Positioning: HOB at 30 degrees in cardiogenic shock (reduces aspiration risk, eases breathing). Never Trendelenburg — it worsens pulmonary edema. |
| 17 | Vasopressor weaning: wean inotropes first once CI improves, then wean vasopressors. Lactate trending to normal and urine output recovering are green lights. |
| 18 | AKI occurs in 50–70% of cardiogenic shock patients. Monitor creatinine, BUN, and hourly urine output. Avoid nephrotoxins. CRRT is preferred over intermittent HD in hemodynamic instability. |
| 19 | Harlequin (north-south) syndrome in VA-ECMO: upper body may be hypoxic while lower body is well-oxygenated. Monitor SpO₂ on the right hand to detect upper body desaturation. |
| 20 | Replace potassium to 4.0–4.5 mEq/L and magnesium to 2.0 mEq/L in cardiogenic shock — electrolyte derangements lower arrhythmia threshold in an already vulnerable myocardium. |
NCLEX scenario questions
| # | Scenario / question | Answer and rationale |
|---|---|---|
| 1 | A patient with anterior STEMI develops SBP 78 mmHg, HR 118, urine output 10 mL/hr, and is confused. Which finding best confirms cardiogenic shock rather than hypovolemic shock? | Elevated PCWP (>15 mmHg). Cardiogenic shock has high filling pressures; hypovolemic shock has low filling pressures. Both cause low BP, tachycardia, and oliguria. |
| 2 | The nurse receives orders for a 1-liter fluid bolus for a patient in cardiogenic shock. The PCWP is 24 mmHg. What is the priority nursing action? | Clarify the order before giving the fluid. PCWP of 24 mmHg confirms volume overload. A fluid bolus could precipitate flash pulmonary edema. Contact the provider to confirm intent. |
| 3 | A patient on norepinephrine and dobutamine has MAP 67, CI 1.6 L/min/m², lactate 5.2 mmol/L, and urine output 0.2 mL/kg/hr. What does this clinical picture indicate? | Refractory cardiogenic shock with inadequate end-organ perfusion despite dual vasoactive support. The patient needs escalation to mechanical circulatory support and urgent revascularization if not yet performed. |
| 4 | Which vasopressor should be used first-line for a patient in cardiogenic shock based on the SOAP-II trial findings? | Norepinephrine. SOAP-II demonstrated that dopamine was associated with significantly more arrhythmias (24.1% vs 12.4%) and worse outcomes in the cardiogenic shock subgroup. Norepinephrine is the preferred first-line agent. |
| 5 | A patient with STEMI and cardiogenic shock has three-vessel coronary disease on emergent angiography. The culprit artery is the LAD. According to CULPRIT-SHOCK trial evidence, what is the preferred PCI strategy? | Culprit-only PCI of the LAD. CULPRIT-SHOCK showed that immediate multivessel PCI increased 30-day mortality compared to culprit-lesion-only PCI. Non-culprit lesions should be staged after stabilization. |
| 6 | A patient receiving Impella CP support develops pink-tinged urine and the LDH is 4,200 U/L. What complication is occurring? | Hemolysis — a known complication of axial-flow pump devices including Impella. The impeller can damage red blood cells. Report to the provider; device positioning and speed may need adjustment. |
| 7 | A patient on VA-ECMO has SpO₂ 99% on the right foot but 84% on the right hand. What syndrome does this represent and what is the nurse's priority? | Harlequin (north-south) syndrome — the native heart is delivering deoxygenated blood to the upper body while ECMO returns well-oxygenated blood to the lower body. Notify the provider; may require adjustment of ECMO flow, addition of VV-ECMO oxygenation, or repositioning of return cannula. |
| 8 | The nurse notes the patient in cardiogenic shock is Killip Class IV. What does this classify mean, and what is the expected mortality? | Killip Class IV is cardiogenic shock — SBP <90, oliguria, altered mentation, cool clammy skin. In-hospital mortality is approximately 40–80% depending on treatment era and revascularization access. |
| 9 | A patient with inferior STEMI develops hypotension, JVP distension, and clear lung fields on auscultation. What is the most likely diagnosis and how does management differ? | Right ventricular infarction. Unlike LV-dominant cardiogenic shock (where fluids worsen pulmonary edema), RV infarction requires careful volume loading to maintain RV preload. Avoid nitrates and diuretics, which drop preload precipitously. |
| 10 | The nurse is caring for a patient in cardiogenic shock who is receiving dobutamine. The patient has been on chronic carvedilol at home. What change in inotrope should the nurse anticipate? | Switching to milrinone. Dobutamine requires beta-adrenergic receptors, which are competitively blocked by carvedilol. Milrinone acts via PDE-3 inhibition downstream of the receptor and remains effective in beta-blocked patients. |
| 11 | A cardiogenic shock patient's lactate was 6.1 mmol/L four hours ago; the current value is 4.8 mmol/L. How should the nurse interpret this trend? | Improvement — a falling lactate indicates improving tissue perfusion and less anaerobic metabolism. Continue current management and continue trending. The goal is lactate <2 mmol/L. |
| 12 | The physician prescribes vasopressin 0.03 units/min as an add-on to the norepinephrine infusion for a patient in refractory cardiogenic shock. What is the rationale? | Vasopressin acts on V1 receptors to cause vasoconstriction without beta-adrenergic stimulation — it raises MAP without increasing heart rate or myocardial oxygen demand. It also allows reduction of norepinephrine dose (reducing adrenergic burden). |
| 13 | During IABP therapy for cardiogenic shock, the nurse notes loss of diastolic augmentation on the waveform and the console alarms "no trigger." What is the priority action? | Assess the patient for rhythm changes (common cause is arrhythmia affecting ECG trigger) and recheck trigger mode. If the patient is in a rhythm without consistent QRS complexes, switch to pressure trigger. Escalate immediately if the cause is not quickly corrected. |
| 14 | Which laboratory trend indicates developing DIC in a cardiogenic shock patient? | Falling fibrinogen + rising D-dimer + prolonged PT/aPTT + falling platelets. DIC causes simultaneous microvascular clotting (consuming clotting factors) and bleeding risk. Alert the provider for DIC-specific treatment. |
| 15 | A patient in cardiogenic shock has potassium 3.1 mEq/L and magnesium 1.4 mEq/L. What is the priority concern? | Increased arrhythmia risk — hypokalemia and hypomagnesemia lower the ventricular fibrillation threshold in an already ischemic myocardium. Replace both before arrhythmias develop. Target K 4.0–4.5 mEq/L and Mg ≥2.0 mEq/L. |
| 16 | Which shock type is characterized by low CO, low PCWP, and low CVP? | Hypovolemic shock. Cardiogenic shock has low CO but high PCWP (>15) and often elevated CVP. Distributive shock (sepsis) has high CO with low SVR. These hemodynamic profiles are tested frequently on NCLEX. |
| 17 | The cardiogenic shock patient who was intubated 6 hours ago has plateau pressure of 34 cmH₂O. What action should the nurse take? | Notify the provider — plateau pressure >30 cmH₂O indicates high airway/lung compliance risk. Anticipate a tidal volume reduction toward 6 mL/kg IBW per lung-protective ventilation protocol. Elevated plateau pressures also reduce venous return and can worsen RV function. |
| 18 | A patient's cardiogenic shock developed after a viral illness in a previously healthy 32-year-old. Which etiology should the nurse suspect? | Fulminant myocarditis — viral or autoimmune inflammation of the myocardium causing acute pump failure. Presents similarly to other CS causes but patient is typically younger without coronary risk factors. Often reversible with MCS support during acute phase. |
| 19 | The IABP balloon catheter is found to have migrated 4 cm distally from its original insertion depth. What is the immediate concern? | The balloon tip may now be near or occluding the renal arteries. Migration distally risks renal artery occlusion, mesenteric ischemia, or aortic bifurcation obstruction. Reposition immediately per physician order; obtain chest X-ray confirmation of tip position. |
| 20 | A cardiogenic shock patient is successfully weaned from vasopressors 48 hours after PCI. The nurse notes the patient is increasingly confused and the CAM-ICU is positive. What condition should be suspected? | ICU delirium. Cardiogenic shock survivors are at high risk for delirium from cerebral hypoperfusion, sedation exposure, sleep disruption, and ICU environment. Implement non-pharmacologic delirium prevention (early mobilization, sleep protocol, reorientation, noise reduction). Assess for reversible causes. |
Summary
Cardiogenic shock is a hemodynamic emergency defined by sustained hypoperfusion from primary pump failure, with cardiac index below 2.2 L/min/m² and elevated filling pressures distinguishing it from other shock states. STEMI is the dominant cause; the Killip classification provides rapid prognostic stratification at the bedside. Management integrates three parallel tracks: pharmacologic support (norepinephrine first-line vasopressor, dobutamine or milrinone for low CI), mechanical circulatory support escalation (IABP for afterload reduction, Impella for direct LV unloading, VA-ECMO for refractory shock), and urgent revascularization (culprit-only PCI for STEMI with multivessel disease, per CULPRIT-SHOCK). Nurses drive the monitoring infrastructure — continuous hemodynamic surveillance via arterial line and PAC, hourly assessment of perfusion markers, multi-organ failure surveillance, and complex device management — that determines whether stabilization or deterioration follows each intervention.
Clinical sources: SOAP-II trial (De Backer et al., NEJM 2010); CULPRIT-SHOCK trial (Thiele et al., NEJM 2017/2018); IABP-SHOCK II trial (Thiele et al., NEJM 2012); Killip-Kimball classification (1967); ACC Expert Consensus Statement on Cardiogenic Shock (JACC 2025); AHA Scientific Statement on Management of Cardiogenic Shock (Circulation 2017); UpToDate — Cardiogenic Shock in AMI; PMC Review of Impella Devices (2022).